S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Facing increasing pressure from customers, some miners are switching to renewable energy
BREAKING: Tiny biotech successfully treats blindness (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
Grant program for Black women entrepreneurs blocked by federal appeals court
The Bio-Tech Stock That Needs Your Attention! (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Facing increasing pressure from customers, some miners are switching to renewable energy
BREAKING: Tiny biotech successfully treats blindness (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
Grant program for Black women entrepreneurs blocked by federal appeals court
The Bio-Tech Stock That Needs Your Attention! (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Facing increasing pressure from customers, some miners are switching to renewable energy
BREAKING: Tiny biotech successfully treats blindness (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
Grant program for Black women entrepreneurs blocked by federal appeals court
The Bio-Tech Stock That Needs Your Attention! (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Federal student loan payments are starting again. Here's what you need to know
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Facing increasing pressure from customers, some miners are switching to renewable energy
BREAKING: Tiny biotech successfully treats blindness (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
Grant program for Black women entrepreneurs blocked by federal appeals court
The Bio-Tech Stock That Needs Your Attention! (Ad)
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
Stock market today: Asian shares mixed as Japan business confidence rises and US shutdown is averted
NASDAQ:GILD

Gilead Sciences (GILD) Earnings Date, Estimates & Call Transcripts

$74.94
-0.48 (-0.64%)
(As of 09/29/2023 08:53 PM ET)
Compare
Today's Range
$74.58
$75.75
50-Day Range
$73.94
$80.67
52-Week Range
$61.44
$89.74
Volume
4.18 million shs
Average Volume
5.73 million shs
Market Capitalization
$93.38 billion
P/E Ratio
17.23
Dividend Yield
4.00%
Price Target
$90.05

Earnings Summary

Upcoming
Earnings Date
Oct. 26Estimated
Actual EPS
(Aug. 3)
$1.34 Missed By -$0.30
Consensus EPS
(Aug. 3)
$1.64
Skip Charts & View Estimated and Actual Earnings Data

GILD Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

GILD Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Gilead Sciences Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20234$1.43$1.92$1.73 
Q2 20235$1.48$1.81$1.61 
Q3 20235$1.46$1.93$1.73 
Q4 20235$1.41$1.92$1.72 
FY 202319$5.78$7.58$6.78 
Q1 20243$1.59$1.97$1.74 
Q2 20243$1.75$1.98$1.85 
Q3 20243$1.85$2.11$2.02 
Q4 20243$1.84$1.88$1.86 
FY 202412$7.03$7.94$7.46 
Q1 20251$1.62$1.62$1.62 
Q2 20251$1.80$1.80$1.80 

GILD Earnings Date and Information

Gilead Sciences last posted its earnings results on August 3rd, 2023. The biopharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by $0.30. The firm had revenue of $6.60 billion for the quarter, compared to analysts' expectations of $6.45 billion. Its revenue for the quarter was up 5.4% on a year-over-year basis. Gilead Sciences has generated $4.35 earnings per share over the last year ($4.35 diluted earnings per share) and currently has a price-to-earnings ratio of 17.2. Earnings for Gilead Sciences are expected to grow by 11.14% in the coming year, from $6.64 to $7.38 per share. Gilead Sciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, October 26th, 2023 based off prior year's report dates.

Gilead Sciences Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
10/26/2023
Estimated)
------- 
8/3/2023Q2 2023$1.64$1.34($0.30)$1.85$6.45 billion$6.60 billion    
4/27/2023Q1 2023$1.63$1.37($0.26)$1.94$6.33 billion$6.35 billion    
2/2/2023Q4 2022$1.50$1.67+$0.17$2.04$6.63 billion$7.39 billion    
10/27/2022Q3 2022$1.44$1.90+$0.46$2.38$6.12 billion$7.04 billion
8/2/2022Q2 2022$1.51$1.58+$0.07$2.25$5.88 billion$6.26 billion
4/28/2022Q1 2022$1.77$2.12+$0.35$4.22$6.28 billion$6.59 billion      
2/1/2022Q4 2021$1.53$0.69($0.84)$1.08$6.64 billion$7.24 billion    
10/28/2021Q3 2021$1.72$2.65+$0.93$3.25$6.31 billion$7.42 billion    
7/29/2021Q2 2021$1.76$1.87+$0.11$2.53$6.15 billion$6.22 billion      
4/29/2021Q1 2021$2.06$2.08+$0.02$2.79$6.78 billion$6.42 billion  
2/4/2021Q4 2020$2.15$2.19+$0.04$3.15$7.11 billion$7.42 billion  
10/28/2020Q3 2020$1.90$2.11+$0.21$3.93$6.20 billion$6.58 billion  












Gilead Sciences Earnings - Frequently Asked Questions

When is Gilead Sciences's earnings date?

Gilead Sciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, October 26th, 2023 based off last year's report dates. Learn more on GILD's earnings history.

Did Gilead Sciences beat their earnings estimates last quarter?

In the previous quarter, Gilead Sciences (NASDAQ:GILD) missed the analysts' consensus estimate of $1.64 by $0.30 with a reported earnings per share (EPS) of $1.34. Learn more on analysts' earnings estimate vs. GILD's actual earnings.

How can I listen to Gilead Sciences's earnings conference call?

The conference call for Gilead Sciences's latest earnings report can be listened to online. Listen to Conference Call

How can I read Gilead Sciences's conference call transcript?

The conference call transcript for Gilead Sciences's latest earnings report can be read online. Read Transcript

How much revenue does Gilead Sciences generate each year?

Gilead Sciences (NASDAQ:GILD) has a recorded annual revenue of $27.28 billion.

How much profit does Gilead Sciences generate each year?

Gilead Sciences (NASDAQ:GILD) has a recorded net income of $4.59 billion. GILD has generated $4.35 earnings per share over the last four quarters.

What is Gilead Sciences's price-to-earnings ratio?

Gilead Sciences (NASDAQ:GILD) has a trailing price-to-earnings ratio of 17.23 and a forward price-to-earnings ratio of 11.29. The price/earnings-to-growth ratio is 0.8.

What is Gilead Sciences's EPS forecast for next year?

Gilead Sciences's earnings are expected to grow from $6.64 per share to $7.38 per share in the next year, which is a 11.14% increase.


More Earnings Resources from MarketBeat

This page (NASDAQ:GILD) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -